ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST CANCER
Clinical trials for ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise in early trial for Hard-to-Treat breast cancer
Disease control Recruiting nowThis early-stage study tests a new oral drug, BBI-940, in people with advanced or metastatic breast cancer that has not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The study aims to find the safest dose and check for s…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Gene mutation may alter how breast cancer responds to hormone therapy
Knowledge-focused Recruiting nowThis study looks at how breast cancer cells change after a short course of hormone therapy in women with and without a BRCA2 gene mutation. Researchers will measure a protein called Ki67, which indicates how fast cancer cells are growing. The goal is to see if BRCA2 carriers have…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST CANCER
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC